GN Corporation will present the results of preclinical and clinical studies with neu REFIX (N-163), one of its Nichi Glucan brand products, in Duchenne muscular dystrophy at the MDA – The Muscular Dystrophy Association – Clinical & Scientific Conference (March 19-22, 2023 in Dallas).
The path-breaking results on the ability of Neu REFIX to aid muscle regeneration and maturation in MDX mice and its clinical efficacy to improve muscle strength in six-month clinical trial including 6MWT, MRC and NSAA will be presented.
Neu REFIX is a beta-glucan food supplement, produced by the N-163 strain of Aureobasidium Pullulans.
